Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649314 | 0.88 | KEAP1 (0.55) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL2068498 | 0.82 | KEAP1 (0.65) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL29904739 | 0.82 | KEAP1 (0.65) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL1855312 | 0.78 | JAK2 (0.49) | PTK2 | |
| SCHEMBL27792302 | 0.77 | PTGS1 (0.68) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL3663376 | 0.77 | MEN1 (0.35) | PTGS1PTGS2L3MBTL1KMT2AGAA | |
| SCHEMBL1488623 | 0.76 | KEAP1 (0.55) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL5313202 | 0.74 | KEAP1 (0.50) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL1488624 | 0.74 | KEAP1 (0.57) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 | |
| SCHEMBL28560347 | 0.73 | PTGS2 (0.57) | PTGS1PTGS2KEAP1L3MBTL1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PTGS1 1113/4885PTGS2 1186/4885KEAP1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.